🟢 Compass Pathways is trading 7.8% up today on continued momentum from Phase 3 depression trial data

Compass Pathways is trading about 7.8% up today at $14.35, extending gains following positive six-month Phase 3 COMP006 trial data for its treatment-resistant depression candidate, COMP360.

• The July 7, 2026, results demonstrated rapid and durable efficacy alongside a consistent safety profile, strengthening the company’s path toward an FDA New Drug Application.
• Investor sentiment remains highly positive as the clinical success suggests a clear trajectory toward potential approval, even amid broader market caution.